In other news, a Food and Drug Administration advisory panel will meet Wednesday to decide whether to recommend approval for a biosimilar drug, which represents a potentially cheaper alternative to Amgen Inc. ’s Neupogen. If it gains agency approval, this drug would be the first biosimilar to get the FDA’s OK and it could mark the beginning of a new […]
On August 4th the Wall Street Journal carried a breathless tale of how a handful of obscure oilfield suppliers were striking immense riches in the sand dunes of Wisconsin. Owing to the “shale revolution”, the stock price of an outfit that had originated in the stagnating business of supplying sand traps to golf courses, and which had been at death’s door as […]
Bloomberg TVTom Lee, the most bullish strategist on Wall Street for the second year in a row.In 2014, Wall Street’s stock market forecasts proved too conservative. The S&P 500 closed the year at 2,058, above the year-end forecast of all but one strategist — FundStrat’s Tom Lee. For 2015, Wall Street sees stocks gaining some ground, but few strategists are calling for […]
Year in Review: The 2014 Financial Market | Wall Street Daily
© 2015 Wall Street Daily, LLC. All rights reserved.105 West Monument Street, Baltimore, MD 21201T. 855.405.3939 or 443.353.4052 F. 410.246.2297
Newsletter FAQ | Cancel Any Time | We Value Your Privacy
Close
Read original article:
Year in Review: The 2014 Financial Market | Wall Street Daily
[…]
Federal Reserve Chairwoman Janet Yellen last week said small-cap stocks appeared to be “substantially stretched.” Now, Goldman Sachs (GS) is on board with a similar view.In a note to clients, Goldman strategist David Kostin said he expects the small-cap Russell 2000 will underperform the S&P 500 over the next 12 months due to pricey valuations and lower earnings forecasts. He […]
Bloomberg TelevisionTom LeeSee AlsoThe Most Hilarious Chart Of 2014This Is The Best Illustration Of History’s Bull And Bear Markets We’ve Seen YetThis Oil Map Answers The First Question Everyone Asks When Turmoil Hits The Middle EastAfter 2013’s 31% gain in the S&P 500, almost no one expected 2014 to see double-digit gains in the US stock market, especially considering the […]
Market Wrap-up for Dec. 29 – The Best Performing Dividend Stocks of 2014By Tom Reese|December 29th, 2014
RSSAs the last few trading days of 2014 draw near, let’s take a look at the dividend-paying stocks that registered the biggest gains on the year.The Ground RulesBefore diving into the list, let’s first establish some ground rules for our study. Here are […]
The New York Stock Exchange is back in play — and it may be sold lock, “stock” and building as soon as next year, The Post has learned.Big Board owner Intercontinental Exchange (ICE) is laying the groundwork. The latest all-out drive to make it more profitable, powered by better and faster technology — and a regulatory overhaul to regain market […]
Markets ended modestly higher on Wednesday’s abbreviated trading session banking on initial claims dropping to a seven-week low and gains in biotechs. The Dow hit a record high for the 37th session and Nasdaq also ended in the green. However, the S&P 500 erased its initial gains and a late selloff dragged the benchmark into the red.For a look at […]
Source: Celgene CorpBiotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer the potential for outsized returns, but they also carry significant risks. To help investors decide which of these clinical-stage companies may be worth considering in 2015, we asked three […]
